According to a recent research report published by Fact.MR, the global basal cell carcinoma treatment market is expected to witness a highly promising growth opportunity in the coming years of the forecast period ranging from 2020 to 2025.
According to a recent research report published by Fact.MR, the global basal cell carcinoma treatment market is expected to witness a highly promising growth opportunity in the coming years of the forecast period ranging from 2020 to 2025. There are five key regions of the global cell carcinoma treatment market viz. North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. Of these, currently, the global market is being dominated by the regional segment of North America. Presence of a highly matured and developed healthcare infrastructure is a key driving factor for the overall development of the North America market.
On the other hand, the regional segment of Asia Pacific is expected to witness promising growth opportunities in the coming years of the forecast period. Increased spending on healthcare infrastructural development by the governments in emerging economies has turned out to be the key driving factor for the development of the Asia Pacific market.
Request a Sample Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=4366
Drugs Segment to Become Key for BCC Market Growth
Healthcare companies working in the global basal cell carcinoma treatment market are now focusing on developing drugs to reduce the incidence or occurrence of the basal cell carcinoma. As such, the drugs segment has emerged as the second-largest revenue grosser amongst the other available treatment options for the diagnosis and treatment of basal cell carcinoma. The projected value of the segment is expected to be around US$2.3 Bn by the end of 2025.
Apart from surgical and other treatment options, drugs are expected to experience exponential growth in adoption during the forecast period of 2020–2025. Healthcare companies in the basal cell carcinoma treatment market are introducing hedgehog pathway inhibitors, a novel drug class for the treatment of basal cell carcinoma. Since BCC is one of the most common cancers in the U.S, companies are increasing production capacities to manufacture hedgehog pathway inhibitor drugs in this region.
“However, the drug is associated with adverse effects in patients, such as muscle spasms and drug-resistance. Hence, companies in the basal cell carcinoma treatment market are assessing the dosing regimens for the effective BCC treatment,” observed Fact.MR
Explore 71 Figures and 36 Tables of the Report. Request the TOC at - https://www.factmr.com/report/4366/basal-cell-carcinoma-treatment-market
Majority Patients to Prefer SRT Treatment Option for Improved Results
Delay in basal cell carcinoma (BCC) treatment can lead to complications regarding the skin, muscle, and even bone damage. Hence, patients suffering from BCC are opting for non-surgical treatments such as superficial radiation therapy (SRT), since this treatment is associated with fewer complications. SRT is gaining increased popularity in the basal cell carcinoma treatment market. This is because conventional radiotherapy treatment has become impractical for dermatologists. Large obsolete machines for conventional SRT are difficult to maintain and are challenging to operate for the average community dermatologist.
“The basal cell carcinoma treatment market is projected for high growth with the introduction of modernized SRT. This growth is further catalyzed with healthcare providers combining SRT with Mohs surgery for the effective treatment of BCC,” states Fact.MR
Healthcare companies in the basal cell carcinoma treatment market can capitalize on this highly-lucrative segment by increasing the availability of SRT in hospitals and specialty clinics. SRT can help companies expand their incremental opportunities, as it can be used for the treatment of other non-melanomas cancers such as squamous cell carcinoma.
Explore Fact.MR’s Lucid Healthcare Coverage
Ophthalmic Drugs Market– The global ophthalmic drugs market shall gain moderate traction during the forecast period (2020-2025), registering a CAGR of 4.2%.
Anticancer Drugs Market – The sales of anticancer drugs are gaining strength, as a large number of awareness campaigns are being initiated by governments and central authorities, at a global level.
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Source: Fact.MR